Folkhälsan Research Center, Helsinki, Finland; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Finland; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia.
Diabetes Res Clin Pract. 2022 Jun;188:109926. doi: 10.1016/j.diabres.2022.109926. Epub 2022 May 14.
We aimed to determine how white blood cell (WBC) telomeres and telomere length change over time are associated with health status in type 1 diabetes.
Relative telomere length (rTL) was measured in WBC DNA from two time-points (median 6.8 years apart) in 618 individuals from the Finnish Diabetic Nephropathy Study by quantitative PCR, with interassay CV ≤ 4%.
Baseline rTL correlated inversely with age and was shorter in men. Individuals in the shortest vs. longest rTL tertile had adverse cardiometabolic profiles, worse renal function, and were prescribed more antihypertensive and lipid-lowering drugs. While overall rTL tended to decrease during the median 6.8-years of follow-up, telomeres shortened in 55.3% of subjects, lengthened in 40.0%, and did not change in 4.7%. Baseline rTL correlated inversely with rTL change. Telomere lengthening was associated with higher HDL-Cholesterol (HDL-C), HDL-C/ApoA1, and with antihypertensive drug and (inversely) with lipid-lowering drug commencement during follow-up. Correlates of rTL percentage change per-annum (adjusted model) were baseline BMI, eGFR, previous retinal laser treatment, HDL-C, and HDL-C/ApoA1.
Telomere length measurements may facilitate the treatment and monitoring of the health status of individuals with type 1 diabetes.
本研究旨在探讨白细胞端粒长度及其随时间的变化与 1 型糖尿病患者健康状况之间的关系。
采用实时荧光定量 PCR 法检测来自芬兰糖尿病肾病研究的 618 例个体在两个时间点（中位数时间间隔为 6.8 年）的白细胞 DNA 中端粒相对长度（rTL），批内变异系数（CV）≤4%。
基线 rTL 与年龄呈负相关，男性 rTL 较短。rTL 最短与最长三分位组的个体具有不良的心血管代谢特征、更差的肾功能，且接受更多的降压和降脂药物治疗。尽管 rTL 整体在中位数 6.8 年的随访期间呈下降趋势，但 55.3%的受试者端粒缩短，40.0%的受试者端粒延长，4.7%的受试者端粒无变化。基线 rTL 与 rTL 变化呈负相关。端粒延长与较高的高密度脂蛋白胆固醇（HDL-C）、HDL-C/ApoA1 以及随访期间降压药物（反之降脂药物）的使用相关。rTL 年变化率的相关因素（调整模型）包括基线 BMI、eGFR、视网膜激光治疗史、HDL-C 和 HDL-C/ApoA1。
端粒长度的测量可能有助于治疗和监测 1 型糖尿病患者的健康状况。
